There are 2789 resources available
1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
Presenter: Natasha B. Leighl
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
Presenter: Catherine A. Shu
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA50 - A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22
Presenter: Anne-Marie Dingemans
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Presenter: Miranda Gogishvili
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1194MO - Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
Presenter: Luis Paz-Ares
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
831MO - Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
Presenter: Yuan-Kai Shi
Session: Mini oral session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
5MO - CDK4/6 blockade is as effective as immune-checkpoint inhibition in tumor growth control of Mlh1-/- and Msh2loxP/loxP villin-Cre mice
Presenter: Inken Salewski
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
6MO - PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways
Presenter: Vincenzo Quagliariello
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
7MO - Effect of anti-CTLA-4 immunotherapy on lymphocyte subset and activation profiles and clonal composition on the B16F0 mouse melanoma model
Presenter: Diana Yuzhakova
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
1801MO - Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors
Presenter: Laetitia Nebot
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast